The Concept of Hormesis in Cancer Therapy - Is Less More?

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Immune system dysregulation and chronic inflammation promote cancer growth and metastasis.
• Traditional cancer therapies require reevaluation in light of immunological advances.
• Novel immunotherapeutic strategies are under development.

Purpose of the Study:

• To explore the 'repositioning' of chemotherapy and radiotherapy based on immunological insights.
• To investigate the application of hormesis in cancer treatment modalities.
• To propose an integrated approach combining repositioned therapies with immunotherapy.

Main Methods:

• Reevaluation of chemotherapy dosing from maximum tolerated dose to low-dose metronomic therapy.
• Application of highly accurate stereotactic targeting for delivering immunogenic doses of radiation.
• Integration of repositioned chemotherapy and radiotherapy with emerging immunotherapeutic procedures.

Main Results:

• Low-dose metronomic chemotherapy may offer an alternative to maximum tolerated dose regimens.
• Stereotactic radiotherapy can deliver ablative, antigen-releasing doses while sparing normal tissues.
• Combining these approaches with immunotherapy shows promise for future cancer treatment.

Conclusions:

• A paradigm shift towards repositioned chemotherapy and radiotherapy is necessary for effective cancer management.
• Hormesis-based dosing strategies (metronomic chemotherapy, immunogenic radiotherapy) can enhance anti-tumor immunity.
• The future of cancer treatment likely involves a combination of repositioned therapies and immunotherapy.